Stock Alert: Liminal BioSciences Jumps 45%

(RTTNews) - Shares of Liminal BioSciences Inc. (LMNL) are surging more than 45 percent or $5.76 in Monday's morning trade at $18.45.

U.S. stocks are rising on Monday in reaction to upbeat news on the coronavirus front. The U.S. Food and Drug Administration or FDA announced Sunday it has issued an emergency use authorization for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients.

Liminal BioSciences is also involved in the collection of convalescent plasma from donors who have recovered from COVID-19. Liminal's lead product candidate is Ryplazim for the treatment of congenital plasminogen deficiency. The biologics license application for Ryplazim is expected to be resubmitted to the FDA in the current third quarter of 2020.

Liminal BioSciences has traded in a range of $5.25 to $31.45 in the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More